Table 1.
Results of univariate logistic regression analysis examining the association between GATA3 mutation status and clinical features.
| Variables | All patients | ER-Positive patients | ||||||
|---|---|---|---|---|---|---|---|---|
| Categories | Wild n (%) | Mutant n (%) | p valuea | OR (95% CI) | Wild n (%) | Mutant n (%) | p valuea | OR (95% CI) |
| Age | ||||||||
| Mean | 58.77 ± 12.97 | 45.66 ± 13.65 | 0.001 | 0.98 (0.96–0.99) | 60.03 ± 13.02 | 54.81 ± 13.68 | 0.00005 |
0.09 (0.95–0.98) |
| Age ≤ 35 | 25 (3%) | 6 (4.3%) | 16 (2.8) | 5 (3.9) | ||||
| Age > 35 | 811 (97%) | 14 (95.7%) | 0.40 | 0.68 (0.27–1.68) | 565 (97.2) | 123 (96.1) | 0.489 |
1.43 (0.52–3.99) |
| Age ≤ 40 | 69 (8.3%) | 20 (14.5%) | 39 (6.7) | 19 (14.8) | ||||
| Age > 40 | 767 (91.7%) | 118 (85.5%) | 0.02 | 0.53 (0.31–0.91) | 542 (93.3) | 109 (85.2) | 0.003 |
2.42 (1.35–4.35) |
| Menopause status | ||||||||
| Peri and Pre | 193 (25.6%) | 53 (43.8%) | 123 (23.3) | 49 (43.4%) | ||||
| Post | 562 (74.4%) | 68 (56.2%) | 0.00004 | 0.44 (0.30–0.65) | 405 (76.7) | 64 (56.6) | 0.00002 |
2.52 (1.61–3.85) |
| Race | ||||||||
| White | 577 (75.8%) | 95 (73.1%) | 418 (81.2) | 85 (70.8) | ||||
| Black/African-American | 138 (18.1%) | 22 (16.9%) | 0.90 | 0.97 (0.59–1.60) | 75 (14.5) | 22 (18.3) | 0.175 |
1.44 (0.85–2.45) |
| Asian | 46 (6.1%) | 13 (10%) | 0.10 | 1.72 (0.89–3.30) | 22 (4.3) | 13 (10.8) | 0.004 |
2.91 (1.41–5.99) |
| History of other malignancy | ||||||||
| No | 783 (93.7%) | 132 (95.7%) | 537 (92.4) | 122 (95.3) | ||||
| Yes | 53 (6.3%) | 6 (4.3%) | 0.37 | 0.67 (0.28–1.59) | 44 (7.6) | 6 (4.7) | 0.253 |
0.60 (0.25–1.44) |
| History of neoadjuvant therapy | ||||||||
| No | 826 (98.8%) | 135 (98.5%) | 572 (98.3) | 125 (98.4) | ||||
| Yes | 10 (1.2%) | 2 (1.5%) | 0.80 | 1.22 (0.27–5.65) | 10 (1.7) | 2 (1.6) | 0.910 |
0.91 (0.20–4.23) |
| Margin status | ||||||||
| Negative | 698 (89.9%) | 117 (88%) | 482 (89.1) | 108 (87.1) | ||||
| Positive/Close | 78 (10.1%) | 16 (12%) | 0.49 | 1.22 (0.69–2.17) | 59 (10.9) | 16 (12.9) | 0.526 |
1.21 (0.67–2.18) |
| Number of involved lymph node | ||||||||
| Median (Q1–Q3) | 2.28 ± 4.46 | 1.95 ± 3.31 | 0.45 | 0.98 (0.93–1.03) | 1 (0–3) | 1 (0–3) | 0.284 |
0.97 (0.91–1.03) |
| Lymph node ratio | ||||||||
| Median (Q1–Q3) | 0.16 ± 0.26 | 0.18 ± 0.27 | 0.56 | 1.25 (0.61–2.57) | 0.06 (0.0–0.25) | 0.06 (0.0–0.24) | 0.756 |
0.88 (0.39–1.98) |
| Lymph node ratio category | ||||||||
| Negative = 0 | 349 (49.4%) | 53 (46.5%) | 218 (44.8) | 48 (45.7) | ||||
| Low (> 0–0.2) | 179 (25.3%) | 29 (25.4%) | 0.79 | 1.07 (0.66–1.74) | 136 (27.9) | 29 (27.6) | 0.902 |
0.97 (0.58–1.61) |
| Intermediate (> 0.2–0.65) | 118 (16.7%) | 23 (20.2%) | 0.36 | 1.28 (0.75–2.19) | 89 (18.3) | 21 (20.0) | 0.812 |
1.07 (0.61–1.79) |
| High (> 0.65) | 61 (8.6%) | 9 (7.9%) | 0.94 | 0.97 (0.46–2.07) | 11 (9.0) | 7 (6.7) | 0.457 |
0.71 (0.31–1.70) |
| AJCC pT | ||||||||
| T1 and T2 | 717 (85.9%) | 106 (77.4%) | 496 (85.4) | 99 (78.0) | ||||
| T3 and T4 | 118 (14.1%) | 31 (22.6%) | 0.01 | 1.78 (1.14–2.77) | 85 (14.6) | 28 (22.0) | 0.040 |
1.65 (1.02–2.66) |
| AJCC pN | ||||||||
| Negative | 398 (48.4%) | 62 (46.6%) | 256 (44.8) | 57 (46.0) | ||||
| Positive | 424 (51.6%) | 71 (53.4%) | 0.70 | 1.07 (0.74–1.55) | 315 (55.2) | 67 (54.0) | 0.818 |
0.95 (0.65–1.41) |
| AJCC pM | ||||||||
| Negative | 702 (97.2%) | 115 (97.5%) | 492 (98.6) | 105 (97.2) | ||||
| Positive | 15 (2.1%) | 3 (2.5%) | 0.76 | 1.22 (0.35–4.28) | 7 (1.4) | 3 (2.8) | 0.318 |
2.01 (0.51–7.89) |
| AJCC stage | ||||||||
| Stage 1 and 2 | 627 (76.7%) | 96 (71.1%) | 428 (75.1) | 90 (72.0) | ||||
| Stage 3 and 4 | 191 (23.3%) | 39 (28.9) | 0.16 | 1.33 (0.89–2.00) | 142 (24.9) | 35 (28.0) | 0.473 |
1.17 (0.76–1.81) |
| ER status by IHC | ||||||||
| Negative | 216 (27.1%) | 1 (0.8%) | – | – | – | – | ||
| Positive | 582 (72.9%) | 128 (99.2%) | 0.0001 | 47.51 (6.60–341.94) | – | – | – | – |
| PR status by IHC | ||||||||
| Negative | 282 (35.5%) | 24 (18.5%) | 83 (14.3) | 23 (18.0) | ||||
| Positive | 513 (64.5%) | 106 (81.5%) | 0.0002 | 2.43 (1.52–3.87) | 497 (85.7) | 105 (82.0) | 0.295 |
0.76 (0.46–1.27) |
| HER2 statusb | ||||||||
| Negative | 589 (81.5%) | 91 (85%) | 431 (81.6) | 91 (85.0) | ||||
| Positive | 134 (18.5%) | 16 (15%) | 0.37 | 0.77 (0.44–1.36) | 97 (18.4) | 16 (15.0) | 0.400 |
0.78 (0.4401.39) |
| Receptor statusc | ||||||||
| ER and/or PR positive | 598 (77.3%) | 129 (100%) | – | – | – | – | ||
| HER2 overexpressed | 32 (4.1%) | 0 (0%) | 1.00 | 0.00 (–) | – | – | – | – |
| TNBC | 144 (18.6%) | 0 (0%) | 1.00 | 0.00 (–) | – | – | – | – |
| Anatomic neoplasm subdivision | ||||||||
| Left | 432 (51.6%) | 75 (54.3%) | 299 (51.4) | 69 (53.9) | ||||
| Right | 405 (48.4%) | 63 (45.7%) | 0.55 | 0.90 (0.62–1.29) | 283 (48.6) | 59 (46.1) | 0.604 |
0.90 (0.62–1.33) |
| Histological type of tumord | ||||||||
| IDC | 617 (73.8%) | 103 (74.6%) | 400 (68.7) | 96 (75.0) | ||||
| ILC | 148 (17.7%) | 14 (10.1%) | 0.06 | 0.57 (0.32–1.02) | 136 (23.4) | 14 (10.9) | 0.005 |
0.43 (0.24–0.78) |
| Other | 71 (8.5%) | 21 (15.2%) | 0.03 | 1.77 (1.04–3.01) | 46 (7.9) | 18 (14.1) | 0.104 |
1.63 (0.91–2.94) |
AJCC American Joint Committee on Cancer, CI confidence interval, ER estrogen receptor, IDC invasive ductal carcinoma, IHC immunohistochemistry, ILC invasive lobular carcinoma, ISH in situ hybridization, OR odds ratio, PR progesterone receptor, TNBC triple negative breast cancer.
aSignificant p values are shown in bold.
bAccording to ISH/IHC results.
cAssociation between the receptor status and GATA3 mutation status cannot be estimated because all GATA3 mutant tumors are also ER and/or PR positive. Significant p values are shown in bold.
dOther category includes rare types of tumors (e.g. Metaplastic, Medullary tumors).